Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Inhaled Corticosteroid Use to Prevent Acute Chest Syndrome Recurrence in Children Between 1 and 4 With Sickle Cell Disease: a Feasibility Trial

NCT02187445 is registered in ClinicalTrials.gov with Vanderbilt University as lead sponsor.

NCT NCT02187445
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02187445 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Inhaled Corticosteroid Use to Prevent Acute Chest Syndrome Recurrence in Children Between 1 and 4 With Sickle Cell Disease: a Feasibility Trial
Lead sponsor
Vanderbilt University
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2014
Completion date
February 13, 2017
Enrollment
36 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute chest syndrome, asthma, sickle cell disease